4D Molecular Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, 4D Molecular Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $27.82. The average 1-year stock price forecast is 89.12% higher than the current stock price, while the lowest is $18 (+22.37%) and the highest is $37 (+151.53%).

Price Target: $27.82 (+89.12%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$18	$27.82	$28	$37
Change	+22.37%	+89.12%	+90.35%	+151.53%

Analyst Ratings

The average analyst rating for 4D Molecular Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	7	7	7	8	8	9
Buy	2	2	2	2	2	2
Hold	2	2	2	2	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Eric Schmidt FCA Cantor Fitzgerald	Cantor Fitzgerald	Buy Upgrades n/a	Buy	Upgrades	n/a	n/a	Sep 21, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $28	Buy	Maintains	$28	+90.35%	Sep 11, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Aug 17, 2026
Daniel Giraldo Bank of America Securities	Bank of America Securities	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 14, 2026
Lisa Walter RBC Capital	RBC Capital	Buy Reiterates $35	Buy	Reiterates	$35	+137.93%	Aug 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

12.77M

from 85.21M

-85.02%

from 85.21M

Revenue Next Year

21.20M

from 12.77M

66.07%

from 12.77M

EPS This Year

-4.14

from -2.42

EPS Next Year

-4.09

from -4.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	18.04M	3.13M	20.72M	37.00K	85.21M	12.77M
Revenue Growth	32.52%	-82.65%	562.29%	-99.82%	230,194.59%	-85.02%
Operating Income	-71.33M	-110.03M	-112.87M	-187.84M	-156.35M	-308.95M
Net Income	-71.32M	-107.49M	-100.84M	-160.87M	-140.11M	-289.69M
EPS	-	-	-	-	-2.42	-4.14
Free Cash Flow	-	-	-	-	-161.56M	-286.71M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	22.5M
Avg	12.8M
Low	6.8M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-73.6%
Avg	-85.0%
Low	-92.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-4.00
Avg	-4.14
Low	-4.28

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-